Safety and Efficacy of Concurrent Administration of Influenza Vaccine in Patients Undergoing Anti-PD-1 Immunotherapy (Nivolumab, Pembrolizumab)

NCT03061955 · clinicaltrials.gov ↗

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Influenza Virus Vaccine Adverse Reaction (Disorder)
Influenza
Malignancy

Interventions

BIOLOGICAL: influenza vaccination

Sponsor

Wake Forest University Health Sciences